Cargando…
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814070/ https://www.ncbi.nlm.nih.gov/pubmed/35115541 http://dx.doi.org/10.1038/s41523-022-00392-3 |
| _version_ | 1784644994469986304 |
|---|---|
| author | Foldi, Julia Silber, Andrea Reisenbichler, Emily Singh, Kamaljeet Fischbach, Neal Persico, Justin Adelson, Kerin Katoch, Anamika Horowitz, Nina Lannin, Donald Chagpar, Anees Park, Tristen Marczyk, Michal Frederick, Courtney Burrello, Trisha Ibrahim, Eiman Qing, Tao Bai, Yalai Blenman, Kim Rimm, David L. Pusztai, Lajos |
| author_facet | Foldi, Julia Silber, Andrea Reisenbichler, Emily Singh, Kamaljeet Fischbach, Neal Persico, Justin Adelson, Kerin Katoch, Anamika Horowitz, Nina Lannin, Donald Chagpar, Anees Park, Tristen Marczyk, Michal Frederick, Courtney Burrello, Trisha Ibrahim, Eiman Qing, Tao Bai, Yalai Blenman, Kim Rimm, David L. Pusztai, Lajos |
| author_sort | Foldi, Julia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8814070 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88140702022-02-16 Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer Foldi, Julia Silber, Andrea Reisenbichler, Emily Singh, Kamaljeet Fischbach, Neal Persico, Justin Adelson, Kerin Katoch, Anamika Horowitz, Nina Lannin, Donald Chagpar, Anees Park, Tristen Marczyk, Michal Frederick, Courtney Burrello, Trisha Ibrahim, Eiman Qing, Tao Bai, Yalai Blenman, Kim Rimm, David L. Pusztai, Lajos NPJ Breast Cancer Author Correction Nature Publishing Group UK 2022-02-03 /pmc/articles/PMC8814070/ /pubmed/35115541 http://dx.doi.org/10.1038/s41523-022-00392-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Foldi, Julia Silber, Andrea Reisenbichler, Emily Singh, Kamaljeet Fischbach, Neal Persico, Justin Adelson, Kerin Katoch, Anamika Horowitz, Nina Lannin, Donald Chagpar, Anees Park, Tristen Marczyk, Michal Frederick, Courtney Burrello, Trisha Ibrahim, Eiman Qing, Tao Bai, Yalai Blenman, Kim Rimm, David L. Pusztai, Lajos Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer |
| title | Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer |
| title_full | Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer |
| title_fullStr | Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer |
| title_full_unstemmed | Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer |
| title_short | Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer |
| title_sort | author correction: neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814070/ https://www.ncbi.nlm.nih.gov/pubmed/35115541 http://dx.doi.org/10.1038/s41523-022-00392-3 |
| work_keys_str_mv | AT foldijulia authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT silberandrea authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT reisenbichleremily authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT singhkamaljeet authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT fischbachneal authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT persicojustin authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT adelsonkerin authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT katochanamika authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT horowitznina authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT lannindonald authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT chagparanees authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT parktristen authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT marczykmichal authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT frederickcourtney authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT burrellotrisha authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT ibrahimeiman authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT qingtao authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT baiyalai authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT blenmankim authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT rimmdavidl authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer AT pusztailajos authorcorrectionneoadjuvantdurvalumabplusweeklynabpaclitaxelanddosedensedoxorubicincyclophosphamideintriplenegativebreastcancer |